Back to search
EGFR Positive Non-small Cell Lung Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which EGFR Positive Non-small Cell Lung Cancer trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which EGFR Positive Non-small Cell Lung Cancer trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This study is a Phase III, international, multicenter, randomized, controlled, open-label clinical trial. The primary objective is to evaluate the efficacy and…
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants wi…
This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients wi…
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participa…
The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.
The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center. T…
This phase II trial studies how well osimertinib with or without bevacizumab works in treating patients with EGFR positive non-small cell lung cancer that has s…
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Recepto…